CSIMarket
 
Altimmune inc   (ALT)
Other Ticker:  
 
 
Price: $9.8600 $-0.17 -1.646%
Day's High: $10.4 Week Perf: -0.1 %
Day's Low: $ 9.75 30 Day Perf: 9.43 %
Volume (M): 14,945 52 Wk High: $ 14.84
Volume (M$): $ 147,356 52 Wk Avg: $5.26
Open: $10.23 52 Wk Low: $2.09



 Market Capitalization (Millions $) 529
 Shares Outstanding (Millions) 54
 Employees 50
 Revenues (TTM) (Millions $) -68
 Net Income (TTM) (Millions $) -78
 Cash Flow (TTM) (Millions $) -41
 Capital Exp. (TTM) (Millions $) 0

Altimmune Inc
Altimmune Inc is a clinical-stage biopharmaceutical company that specializes in developing and commercializing therapies for the treatment of infectious diseases, immunological disorders, and liver diseases. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Altimmune uses a proprietary technology platform, called RespirVec, to develop its vaccines and immunotherapies. RespirVec is a respiratory virus-based vector system that enables the efficient delivery of antigens directly to the immune system, resulting in a robust immune response. The platform is highly versatile, with the ability to deliver a wide range of vaccine candidates and therapeutic proteins.

One of Altimmune's lead programs is the development of a single-dose, intranasal COVID-19 vaccine candidate, AdCOVID. This vaccine uses Altimmunees RespirVec technology to deliver the spike protein antigen of SARS-CoV-2, the virus that causes COVID-19. The company is currently conducting Phase 1 trials for AdCOVID, and is confident that the vaccine will be effective in preventing COVID-19, both in the initial pandemic and in future waves.

Altimmune has a robust pipeline of other infectious disease programs, including a hepB vaccine, a flu vaccine, and an anthrax vaccine. The company is also developing immunotherapies for chronic hepatitis B, Alpha-1 Antitrypsin Deficiency, and NASH (non-alcoholic steatohepatitis).

Altimmune maintains partnerships and collaborations with other leading biopharmaceutical companies, including the University of Alabama at Birmingham, the University of Maryland School of Medicine, and the University of North Carolina at Chapel Hill. These collaborations give Altimmune access to world-class research facilities, expertise, and resources.

Overall, Altimmune Inc is a cutting-edge biopharmaceutical company that is at the forefront of developing innovative therapies for some of the world's most pressing health issues. With its strong pipeline, proprietary technology platform, and collaborative approach, Altimmune is well-suited to continue making significant contributions to the field of biopharmaceuticals.


   Company Address: 910 Clopper Road Gaithersburg 20878 MD
   Company Phone Number: 654-1450   Stock Exchange / Ticker: NASDAQ ALT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Altimmune's MOMENTUM Trial Shows Promise in Obesity Treatment: Revenue Challenges Spurs Investor Anticipation

Published Thu, Nov 30 2023 9:24 PM UTC

Altimmune Inc. Reports Positive Results from 48-Week Phase 2 Obesity Trial of Pemvidutide
Altimmune Inc., a clinical-stage biopharmaceutical company, has announced positive topline results from its MOMENTUM Phase 2 trial evaluating the efficacy and safety of Pemvidutide for the treatment of obesity. The company will be hosting a conference call tomorrow at 8:30 am EST to...

Altimmune Inc

Altimmune Inc Soars to New Heights: Revenue Surges by 18000% in Q3, 2023

Altimmune Inc, a biopharmaceutical company based in the United States, recently announced strong revenue growth of $0.36 million for the financial period ending September 30, 2023. Although the company reported a loss of $-0.39 million during the same period, this figure marks an improvement compared to the prior quarter.
The significant increase in the company's deficit from $-0.32 per share in the prior quarter, coupled with a remarkable 5933.333% surge in revenue from $0.01 million, showcases Altimmune Inc's substantial growth. The financial report for the period ending September 30, 2023, also reveals a net deficit of $-20.671 million, a narrower loss compared to the $-23.516 million from the equivalent quarter in the previous year.

Altimmune Inc

Altimmune Inc Shows Promising Financial Results in Q2 2023 Despite Revenue Decline



Altimmune Inc, a biopharmaceutical company, showed promising results in the financial period from April to June 30, 2023. The company experienced a decrease in loss per share, improved earnings per share, and a decline in the net shortfall compared to the previous year. However, a sharp decline in revenue raises concerns about the company's performance. This article will outline the key financial figures reported by Altimmune Inc in Q2 2023 and discuss the possible reasons behind the decline in revenue.
Decreased Loss and Improved Earnings:
Altimmune Inc managed to decrease its loss per share from $-0.42 in the same reporting period last year to $-0.32 per share in Q2 2023. This improvement demonstrates the company's ability to control costs and streamline operations. Earnings per share also saw an improvement, increasing from $-0.39 per share in the previous reporting season to an undisclosed higher amount. These positive developments indicate the company's ongoing efforts to become financially stable and increase shareholder value.

Altimmune Inc

Altimmune Inc Faces Challenging First Quarter Performance, Record Decline in Revenue

Altimmune Inc is a pharmaceutical company that is dedicated to the development of immunotherapeutics for the treatment of various diseases. Headquartered in Maryland, United States, the company has a primary focus on immune-based therapies that are designed to tackle a range of diseases, including infectious diseases, cancer and autoimmune diseases. The company operates within the major pharmaceutical preparations industry, which has seen growth in average income per employee but unfortunately, Altimmune Inc's overall ranking has deteriorated compared to the previous quarter.
A closer look at the financial results of Altimmune Inc shows that there has been some improvement in terms of earnings per share (EPS). For the most recent fiscal period, the company decreased its loss per share from $-0.44 to $-0.39. This represents a significant improvement compared to the previous year, where the EPS was at $-0.46 per share from the preceding quarter. However, despite the improvements in the EPS, the company saw a steep decline in revenue, which fell by -60.377% to $0.02 million. This is a significant decline compared to the $0.05 million in the comparable quarter a year prior. It is worth noting that sequentially revenue turned positive from $-68.00 million.






 

Altimmune Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com